These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30451936)

  • 21. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.
    Opoka-Winiarska V; Jurecka A; Emeryk A; Tylki-Szymańska A
    Osteoarthritis Cartilage; 2013 Dec; 21(12):1813-23. PubMed ID: 23954699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unique medical issues in adult patients with mucopolysaccharidoses.
    Mitchell J; Berger KI; Borgo A; Braunlin EA; Burton BK; Ghotme KA; Kircher SG; Molter D; Orchard PJ; Palmer J; Pastores GM; Rapoport DM; Wang RY; White K
    Eur J Intern Med; 2016 Oct; 34():2-10. PubMed ID: 27296591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanotechnology applied to treatment of mucopolysaccharidoses.
    Schuh RS; Baldo G; Teixeira HF
    Expert Opin Drug Deliv; 2016 Dec; 13(12):1709-1718. PubMed ID: 27322551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
    Muenzer J
    Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on ocular involvement in mucopolysaccharidoses.
    Ganesh A; Bruwer Z; Al-Thihli K
    Curr Opin Ophthalmol; 2013 Sep; 24(5):379-88. PubMed ID: 23872816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging drugs for the treatment of mucopolysaccharidoses.
    Giugliani R; Federhen A; Vairo F; Vanzella C; Pasqualim G; da Silva LM; Giugliani L; de Boer AP; de Souza CF; Matte U; Baldo G
    Expert Opin Emerg Drugs; 2016; 21(1):9-26. PubMed ID: 26751109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapies for the bone in mucopolysaccharidoses.
    Tomatsu S; Alméciga-Díaz CJ; Montaño AM; Yabe H; Tanaka A; Dung VC; Giugliani R; Kubaski F; Mason RW; Yasuda E; Sawamoto K; Mackenzie W; Suzuki Y; Orii KE; Barrera LA; Sly WS; Orii T
    Mol Genet Metab; 2015 Feb; 114(2):94-109. PubMed ID: 25537451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses.
    Safary A; Moghaddas-Sani H; Akbarzadeh-Khiavi M; Khabbazzi A; Rafi MA; Omidi Y
    Expert Opin Biol Ther; 2021 Sep; 21(9):1181-1197. PubMed ID: 33653197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene therapies for mucopolysaccharidoses.
    Rossi A; Brunetti-Pierri N
    J Inherit Metab Dis; 2024 Jan; 47(1):135-144. PubMed ID: 37204267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms.
    Shapiro EG; Jones SA; Escolar ML
    Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments.
    Sawamoto K; Stapleton M; Alméciga-Díaz CJ; Espejo-Mojica AJ; Losada JC; Suarez DA; Tomatsu S
    Drugs; 2019 Jul; 79(10):1103-1134. PubMed ID: 31209777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Possible strategies to cross the blood-brain barrier.
    Bellettato CM; Scarpa M
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):131. PubMed ID: 30442184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS.
    Byers S; Rozaklis T; Brumfield LK; Ranieri E; Hopwood JJ
    Mol Genet Metab; 1998 Dec; 65(4):282-90. PubMed ID: 9889015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
    Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
    Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systems biology study of mucopolysaccharidosis using a human metabolic reconstruction network.
    Salazar DA; Rodríguez-López A; Herreño A; Barbosa H; Herrera J; Ardila A; Barreto GE; González J; Alméciga-Díaz CJ
    Mol Genet Metab; 2016 Feb; 117(2):129-39. PubMed ID: 26276570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucopolysaccharidosis-Plus Syndrome.
    Vasilev F; Sukhomyasova A; Otomo T
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation in VPS33A affects metabolism of glycosaminoglycans: a new type of mucopolysaccharidosis with severe systemic symptoms.
    Kondo H; Maksimova N; Otomo T; Kato H; Imai A; Asano Y; Kobayashi K; Nojima S; Nakaya A; Hamada Y; Irahara K; Gurinova E; Sukhomyasova A; Nogovicina A; Savvina M; Yoshimori T; Ozono K; Sakai N
    Hum Mol Genet; 2017 Jan; 26(1):173-183. PubMed ID: 28013294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy for the mucopolysaccharidoses.
    Valayannopoulos V; Wijburg FA
    Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v49-59. PubMed ID: 22210671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and II clinical trials for the mucopolysaccharidoses.
    Poswar F; Baldo G; Giugliani R
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1331-1340. PubMed ID: 29065735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.